ADOA

Comtech Partners with Arizona to Complete Transition to Statewide Next Generation 911 Services

Retrieved on: 
Wednesday, April 10, 2024
Semiconductor, Security, Aerospace, Satellite, Manufacturing, Audio, Video, Other Technology, Telecommunications, Software, Networks, Internet, Hardware, Electronic Design Automation, VoIP, Technology, Mobile, Wireless, Public Policy, Government, Law Enforcement, Emergency Services, Public Safety, CMTL, ADOA, State, Partnership, Emergency, Arizona Department, Emergency service, Interim

April 10, 2024-- Comtech (NASDAQ: CMTL) (the “Company”), a global technology leader, in partnership with the Arizona Department of Administrations (“ADOA”), today announced the successful completion of a statewide transition to Comtech’s Next Generation 911 (“NG911”) services.

Key Points: 
  • April 10, 2024-- Comtech (NASDAQ: CMTL) (the “Company”), a global technology leader, in partnership with the Arizona Department of Administrations (“ADOA”), today announced the successful completion of a statewide transition to Comtech’s Next Generation 911 (“NG911”) services.
  • Arizona’s new statewide NG911 infrastructure is designed to significantly enhance the ability of first responders and public safety answering points (“PSAPs”) to respond faster to emergencies and provide more comprehensive and reliable 911 services to Arizona residents.
  • In less than two years, Comtech and the ADOA successfully migrated the state’s legacy 911 system to the new infrastructure.
  • “With this statewide deployment, Arizona residents benefit from a much higher rate of call reliability and new multi-media and location services, which can save critical time during emergencies.

Stoke Therapeutics Highlights Strategic Priorities and Anticipated Milestones for 2024

Retrieved on: 
Monday, January 8, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, CSF, RNA, Conference, Cognition, Dravet syndrome, Acadia Pharmaceuticals, Cerebrospinal fluid, Rett syndrome, American Epilepsy Society, Brain, IRB, Therapy, Behavior, ADOA, CNS, Webcast, Central nervous system, Patient, Medicine, MECP2, OLE, SYNGAP1, Stoke, Pharmaceutical industry

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced strategic priorities and anticipated milestones for 2024.

Key Points: 
  • Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced strategic priorities and anticipated milestones for 2024.
  • 2024 is all about advancing this potential new medicine toward a registrational study,” said Edward M. Kaye, M.D., Chief Executive Officer of Stoke Therapeutics.
  • Stoke ended the third quarter of 2023 with $214.7 million in cash, cash equivalents and marketable securities, anticipated to fund operations to the end of 2025.
  • Stoke’s Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
    Dr. Edward Kaye will discuss Stoke’s strategic priorities and anticipated milestones in a presentation at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 6:45 p.m.

Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates

Retrieved on: 
Monday, August 7, 2023
Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Genetics, Clinical Trials, Cognition, Seizure, Therapy, American Epilepsy Society, Health care, FALCON, CTA, Medicine, Dravet syndrome, Oles, Congress, Patient, ADOA, Acadia Pharmaceuticals, OPA1, ASO, Diagnosis, AES, License, Stoke, Collaboration, Safety, Behavior, MHRA, Disease, Pharmaceutical industry, Cryptocurrency

“We recently shared positive new data supporting the potential for STK-001 as the first disease-modifying treatment for Dravet syndrome.

Key Points: 
  • “We recently shared positive new data supporting the potential for STK-001 as the first disease-modifying treatment for Dravet syndrome.
  • Single and multiple doses of STK-001 from 10mg up to 70mg have been generally well tolerated.
  • During the quarter ended June 30, 2023, Stoke updated its estimate of the total effort it expected to expend to satisfy its performance obligations under the Acadia collaboration.
  • As a result, Stoke recorded a cumulative catch-up adjustment of $(5.3) million which resulted in a reversal of revenue during the quarter ended June 30, 2023.

Abeona Therapeutics Reports First Quarter 2023 Financial Results

Retrieved on: 
Thursday, May 11, 2023
PRV, Gene, Stargardt disease, Priority review, ISID, Drug discovery, Stargardt, Concha bullosa, AAV, Investment, International Society for Infectious Diseases, ADOA, Cell, Webcast, Research, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, Safety, BLA, Society, Food, Pharmaceutical industry, Cryptocurrency, RDEB, List of Roman birth and childhood deities

CLEVELAND, May 11, 2023 (GLOBE NEWSWIRE) --  Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the first quarter of 2023 and provided an update on progress toward achieving key corporate objectives.

Key Points: 
  • Continues to make progress toward Biologics License Application (BLA) submission for EB-101 in late-2Q/early-3Q 2023; submitted request for pre-BLA meeting
    Reiterates cash runway guidance into 3Q 2024, beyond anticipated timing for EB-101 BLA potential approval
    CLEVELAND, May 11, 2023 (GLOBE NEWSWIRE) --  Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the first quarter of 2023 and provided an update on progress toward achieving key corporate objectives.
  • The Company has been granted pre-Investigational New Drug Application meetings for two of its programs to take place in the second quarter of 2023.
  • “Our operating cash burn for the first quarter of 2023 and projected operating cash burn for the second quarter of 2023 include BLA submission and personnel costs, which we expect will be substantially lower in the second half of 2023,” said Joe Vazzano, Chief Financial Officer of Abeona.
  • License and other revenues in the first quarter of 2023 were nil, compared to $0.3 million in the first quarter of 2022.

Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates

Retrieved on: 
Thursday, May 4, 2023
Research, FDA, Neurology, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Seizure, Therapy, Health care, Quality of life, CTA, Medicine, Dravet syndrome, Cerebrospinal fluid, Patient, ADOA, Optic nerve, ASO, CSF, License, Collaboration, Safety, Caregiver, MHRA, Disease, Pharmaceutical industry, Vaccine, Cryptocurrency, Stoke

Dravet syndrome is a severe and progressive genetic epilepsy characterized by frequent, prolonged and refractory seizures beginning within the first year of life.

Key Points: 
  • Dravet syndrome is a severe and progressive genetic epilepsy characterized by frequent, prolonged and refractory seizures beginning within the first year of life.
  • Complications of the disease often contribute to poor quality of life for patients and their caregivers.
  • Despite available anti-seizure medicines, seizures are not adequately controlled for more than 90% of patients.
  • The analysis will include safety, pharmacokinetic (PK), and cerebrospinal fluid (CSF) drug exposure data from the MONARCH and ADMIRAL studies.

Stoke Therapeutics Receives Authorization to Initiate a Phase 1/2 Study of STK-002 for Autosomal Dominant Optic Atrophy (ADOA) in the United Kingdom

Retrieved on: 
Tuesday, April 25, 2023
Research, FDA, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, Optical, Science, Central nervous system, Life, Serum, DSM-IV codes, FALCON, Health care, Eye, Quality of life, CTA, TANGO, Trial of the century, IVT, Haploinsufficiency, Patient, ADOA, OPA1, ASO, Diagnosis, Stoke, Paratriathlon, Therapy, Safety, MHRA, Disease, Pharmaceutical industry, Vaccine

ADOA is a rare disease that causes progressive and irreversible vision loss in both eyes starting in the first decade of life.

Key Points: 
  • ADOA is a rare disease that causes progressive and irreversible vision loss in both eyes starting in the first decade of life.
  • STK-002 is a proprietary antisense oligonucleotide (ASO) being developed by Stoke as the first potential disease-modifying therapy to address the genetic cause of ADOA.
  • STK-002 is designed to restore OPA1 protein expression by upregulating protein production from the non-mutant (wild-type) copy of the OPA1 gene.
  • By doing this, the company hopes to slow or even stop vision loss in patients with ADOA.

Abeona Therapeutics Announces Multiple Abstracts Accepted from its AAV Ophthalmology Program at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Retrieved on: 
Monday, April 10, 2023
Abstract, Gene, Stargardt disease, Stargardt, AAV, ADOA, Cell, Research, FDA, Society, Vaccine

CLEVELAND, April 10, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the acceptance of three abstracts at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) taking place from May 16-20, 2023 in Los Angeles, CA.

Key Points: 
  • CLEVELAND, April 10, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the acceptance of three abstracts at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) taking place from May 16-20, 2023 in Los Angeles, CA.
  • Accepted abstracts include new data on three internally developed investigational preclinical gene therapy product candidates from its adeno-associated virus (AAV) ophthalmology program, including ABO-504 for Stargardt disease, ABO-503 for X-linked retinoschisis (XLRS) and ABO-505 for autosomal dominant optic atrophy (ADOA).
  • “We have started to submit pre-IND meeting requests to the FDA for our gene therapy product candidates and anticipate meetings to take place in the second quarter of 2023.
  • We are excited for the opportunity to share our new data with the scientific community at ASGCT.”
    Details for the poster presentations are as follows:

Abeona Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, March 29, 2023
Biologics license application, CLN1, Business development, PRV, Priority review, ISID, Drug discovery, Rett syndrome, Stargardt, Bristol Myers Squibb, Holocene, Concha bullosa, AAV, MSHS, Rare, Dermatology, Eye, Orphanet Journal of Rare Diseases, Patient, Investment, International Society for Infectious Diseases, Ophthalmology, ADOA, Congress, Retinoschisis, FDA, Research, Therapy, Regulation of tobacco by the U.S. Food and Drug Administration, IND, Global marketing, BLA, Food, Wound healing, Medical imaging, Pharmaceutical industry, Vaccine, Cryptocurrency, Stargardt disease, RDEB, List of Roman birth and childhood deities

NEW YORK and CLEVELAND, March 29, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the full year of 2022 and provided an update on progress toward achieving key corporate objectives. The Company will host a conference call and webcast today, March 29, 2023, at 8:30 a.m. ET, to discuss its financial results and business update.

Key Points: 
  • ET, to discuss its financial results and business update.
  • The Company currently plans to submit a BLA for EB-101 in late second quarter to early third quarter of 2023.
  • Abeona appointed Dmitriy Grachev, M.D., Ph.D., as Chief Medical Officer and Madhav Vasanthavada, Ph.D., M.B.A. as Vice President, Business Development.
  • Abeona Therapeutics will host a conference call and webcast today, March 29, 2023, at 8:30 a.m.

Abeona Therapeutics Announces Update on AAV Ophthalmology Program

Retrieved on: 
Tuesday, March 14, 2023
Messenger, Eye, Annual general meeting, Retinoschisis, ADOA, Brain, ABCA4, Cell, Visual acuity, RS1, AAV, Association for Research in Vision and Ophthalmology, ARVO, Architecture, Optic nerve, Retina, Stargardt disease, Research, Animal, RGC, IND, Vaccine, Ophthalmology

NEW YORK and CLEVELAND, March 14, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced three internally developed investigational preclinical gene therapy product candidates from its ophthalmology program. Abeona’s preclinical programs are investigating the use of novel adeno-associated virus (AAV) capsids in therapies for serious genetic eye diseases.

Key Points: 
  • Abeona’s preclinical programs are investigating the use of novel adeno-associated virus (AAV) capsids in therapies for serious genetic eye diseases.
  • “We are excited by the broad potential for treating serious eye diseases with new AAV-based therapies using novel AAV capsids from our in-licensed AIM™ capsid library and internal research,” said Brian Kevany, Ph.D., Chief Technical Officer and Head of Research at Abeona.
  • In May 2021 at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, Abeona reported preclinical data demonstrating the ability of the dual AAV vector system to produce full length ABCA4 protein in cell culture.
  • Initial efficacy results suggest an improvement in retinal signaling to the brain, and improved visual acuity in treated mutant mice.

Stoke Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

Retrieved on: 
Monday, March 6, 2023
Research, FDA, Neurology, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Therapy, CTA, Seizure, Medicine, Central nervous system, Patient, Function (mathematics), Disease, Collaboration, ADOA, License, Dravet syndrome, Stoke, Syndrome, Vaccine, Pharmaceutical industry, Telescope, Drug, Cryptocurrency

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results for the full year ended December 31, 2022 and provided business updates.

Key Points: 
  • Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results for the full year ended December 31, 2022 and provided business updates.
  • Research and development expenses for the year ended December 31, 2022 were $77.8 million, compared to $54.2 million for 2021.
  • General and administrative expenses for the year ended December 31, 2022 were $38.9 million, compared to $31.9 million for 2021.
  • As of December 31, 2022, Stoke had $230.2 million in cash, cash equivalents, marketable securities, and restricted cash.